Launching Beacon Therapeutics

Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, today announces that it has launched Beacon Therapeutics, a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, with a £96 million Series A financing. The new portfolio company has been created by Syncona through the combination of Applied Genetic Technologies Corporation's (AGTC's) late-stage programme in X-linked retinitis pigmentosa (XLRP), with two other innovative pre-clinical programmes.